CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|June 1, 2016
- BioPharm International-06-01-2016
- Volume 29
- Issue 6
Sensors Allow for Bluetooth Connectivity
The ArcAir communication package from Hamilton Company enables Bluetooth 4.0 wireless connectivity in all environments.
Advertisement
The ArcAir communication package from Hamilton Company enables Bluetooth 4.0 wireless connectivity in all environments. The Bluetooth capability allows users to view or control Hamilton Arc Sensors from devices including smart phones and tablets. ArcAir apps are available online for Android and iOS platforms. The arc sensors are measuring tools that contain a built-in microprocessor and provide direct digital and analog communication. The ArcAir mobile application for Arc pH, dissolved oxygen, and conductivity measurement can communicate wirelessly with up to 30 individual sensors at the same time. Hamilton also offers a Bluetooth version of its GMP Compliance Package, which works with ArcAir Advanced and provides centralized management of users and validation reports for calibration, verification, configuration, and communication within the GMP guidelines for all Arc sensors.
Articles in this issue
over 10 years ago
Watch Out for the Hangoverover 10 years ago
Scale-Up of Complex Biologicsover 10 years ago
Essentials in Tolerance Design and Setting Specification Limitsover 10 years ago
Make Data Integrity Integral to CGMP Trainingover 10 years ago
Continued Process Verification: State of the Industryover 10 years ago
Scaling Up Progressive Expression Systemsover 10 years ago
Bioprocessing Technology Marches Onover 10 years ago
Controlling Glycosylation for Improved Product Qualityover 10 years ago
Modern Manufacturing Comes of Ageover 10 years ago
Biosimilars: Making the Switch Comes with ChallengesAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement